Division of Pharmacoepidemiology and Pharmacotherapy, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, The Netherlands.
Biomarkers. 2011 Feb;16(1):51-7. doi: 10.3109/1354750X.2010.526243. Epub 2010 Oct 27.
A biomarker for discriminating mechanisms of chemotherapy-induced thrombocytopenia (CIT) (i.e. increased platelet destruction and decreased platelet production) would be valuable in managing treatment.
We explored the discriminating value of platelet size indices for this purpose in a population of adult oncology patients.
Mean platelet volume (MPV) and platelet distribution width (PDW) were compared between patients with (i) thrombocytopenia possibly due to increased platelet destruction; (ii) thrombocytopenia possibly due to decreased platelet destruction; and (iii) no thrombocytopenia.
We obtained negative results, suggesting that these indices are not useful for discriminating different CIT mechanisms.
区分化疗引起的血小板减少症（CIT）的机制（即血小板破坏增加和血小板生成减少）的生物标志物对于治疗管理非常有价值。
我们在成年肿瘤患者人群中探索血小板大小指数在这方面的区分价值。
比较血小板减少症可能由于血小板破坏增加的患者（i）、血小板减少症可能由于血小板破坏减少的患者（ii）和无血小板减少症患者（iii）之间的平均血小板体积（MPV）和血小板分布宽度（PDW）。
我们得到了否定的结果，表明这些指数对于区分不同的 CIT 机制并不有用。
